Clinical trial
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation…
NCT00064337 · SWOG Cancer Research Network, Other · Completed
Key facts
| NCT number | NCT00064337 |
|---|---|
| Title | S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis |
| Official title | S0115, A Phase II Trial Evaluating Modified High Dose Melphalan (100 mg/m) And Autologous Peripheral Blood Stem Cell Supported Transplant (SCT) For High Risk Patients With Multiple Myeloma And/Or Light Chain Amyloidosis (AL Amyloidosis) (A BMT Study) |
| Lead sponsor | SWOG Cancer Research Network, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma, Plasma Cell Myeloma |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, cyclophosphamide, dexamethasone, melphalan, thalidomide, peripheral blood stem cell transplantation |
| Enrollment | 104 |
| Start date | Jan 1, 2004 |
| Primary completion | May 1, 2012 |
| Completion | Nov 1, 2015 |
| First posted | Jul 9, 2003 |
| Last update posted | Aug 9, 2018 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: